Online citations, reference lists, and bibliographies.
← Back to Search

Enhanced Pharmacological Activity Of Recombinant Human Interleukin-11 (rhIL11) By Chemical Modification With Polyethylene Glycol.

A. Takagi, N. Yamashita, T. Yoshioka, Yuuki Takaishi, K. Sano, H. Yamaguchi, A. Maeda, K. Saito, Y. Takakura, M. Hashida
Published 2007 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
In order to improve the pharmacological efficacy of recombinant human interleukin-11 (rhIL11) and to reduce the frequency of administration, we examined the feasibility of chemical modification of rhIL11 by polyethylene glycol. The rhIL11 was chemically modified by using branched type (PEG2), or linear type (PEG) polyethylene glycol-N-hydroxysuccinimide with various molecular weights. Plasma profiles of immunoreactive rhIL11 after i.v. injection of the 20 kDa PEG2 conjugated rhIL11 (PEG2 (20 K)-rhIL11) were determined by ELISA. Peripheral platelet counts after the administration of the various conjugates were measured. Pharmacokinetic analysis revealed that the mean residence time of PEG2 (20 K)-rhIL11 after i.v. injection extensively increased by a factor of ca 60 compared with the native rhIL11. Maximum peripheral platelet increase of 67% for PEG2 (20 K)-rhIL11 and that of 50% for PEG (20 K)-rhIL11 over the control was observed whereas no significant change was associated with the bolus i.v. injection of native rhIL11. On the other hand, the remaining biological activity of these PEGylated-rhIL11s was 14-16% of native rhIL11, suggesting that retention of rhIL11 in plasma is much effective in order to potentiate the pharmacological efficacy of the cytokine. Chemical modification of rhIL11 by PEG is a promising approach for improving the clinical efficacy of rhIL11 by prolonged retention in plasma.
This paper references
10.1182/BLOOD.V89.11.3897
Interleukin-11: review of molecular, cell biology, and clinical use.
X. Du (1997)
10.1038/11717
Therapeutic antibody fragments with prolonged in vivo half-lives
A. P. Chapman (1999)
10.1182/BLOOD.V81.4.965.BLOODJOURNAL814965
In vivo effects of recombinant interleukin-11 on myelopoiesis in mice.
G. Hangoc (1993)
10.1203/00006450-199307000-00014
Effect of Interleukin-11 with and without Granulocyte Colony-Stimulating Factor on In Vivo Neonatal Rat Hematopoiesis: Induction of Neonatal Thrombocytosis by Interleukin-11 and Synergistic Enhancement of Neutrophilia by Interleukin-11 + Granulocyte Colony-Stimulating Factor
M. Cairo (1993)
Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow.
A. Orazi (1996)
10.1021/BC000082G
Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
P. Bailon (2001)
10.1046/j.1365-2141.2001.02508.x
Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino‐protective reagent
S. Tsunoda (2001)
10.1111/j.1365-2141.1993.tb03020.x
Effect of recombinant human interleukin‐11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin‐6
Y. Yonemura (1993)
10.1093/JAOAC/83.5.1053
Quantitative in vitro bioassay for recombinant human interleukin-11.
H. Yokota (2000)
10.1002/JPS.2600840511
Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist.
D. C. Kim (1995)
10.1038/nbt812
Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity
Y. Yamamoto (2003)
The fate of interleukin-2 after in vivo administration.
J. Donohue (1983)
10.1152/AJPRENAL.1978.234.6.F455
Glomerular permselectivity: barrier function based on discrimination of molecular size and charge.
B. Brenner (1978)
10.1038/bjc.1996.495
Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
Y. Tsutsumi (1996)
10.1111/j.1749-6632.1995.tb32323.x
Alanine‐scanning Mutagenesis of Human Interleulcin‐11: Identification of Regions Important for Biological Activity
M. Czupryn (1995)
10.1002/JCB.240360405
Human cytokines, tumor necrosis factor, and interferons: Gene cloning, animal studies, and clinical trials
A. Bollon (1988)
10.1111/J.1432-1033.1988.TB14384.X
Genes coding for RNA polymerase β subunit in bacteria
Nicholay A. Lisitsyn (1988)
10.1021/BC00031A006
A branched monomethoxypoly(ethylene glycol) for protein modification.
C. Monfardini (1995)
10.1182/BLOOD.V87.9.3607.BLOODJOURNAL8793607
A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.
I. Tepler (1996)
10.1023/A:1012063602856
Renal Disposition of Recombinant Human Interleukin-11 in the Isolated Perfused Rat Kidney
A. Takagi (2004)
10.1007/s002800051048
Effect of interleukin 11 on normal and pathological thrombopoiesis
M. Teramura (1996)
10.1038/KI.1979.128
Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review.
T. Maack (1979)
10.1159/000046557
Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01
G. Morstyn (2001)
10.1182/BLOOD.V86.1.73.BLOODJOURNAL86173
Accelerated cell-cycling of hematopoietic progenitor cells by growth factors.
R. Tanaka (1995)
10.1271/BBB.60.541
Importance of the carboxy-terminus of human interleukin-11 in conserving its biological activity.
K. Miyadai (1996)
10.1074/JBC.270.2.978
Structure-Function Relationships in Human Interleukin-11
M. Czupryn (1995)
10.1038/bjc.1995.186
Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.
Y. Tsutsumi (1995)
10.1111/J.1432-1033.1988.TB14383.X
Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.
J. Castell (1988)
10.1182/BLOOD.V87.9.3615.BLOODJOURNAL8793615
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
M. Gordon (1996)
10.1182/BLOOD.V81.4.901.BLOODJOURNAL814901
Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice.
T. Neben (1993)
10.1016/J.BBRC.2004.01.125
Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency
Y. Yoshioka (2004)
10.1007/s002800051047
Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy
M. Gordon (1996)
Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
J. Leonard (1996)
Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.
A. Takagi (1995)
10.1074/jbc.272.4.2312
Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling*
D. Pettit (1997)
10.1073/PNAS.89.9.4013
Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors.
A. G. Leary (1992)
Pharmacokinetics of recombinant human granulocyte colony-stimulating factor studied in the rat by a sandwich enzyme-linked immunosorbent assay.
H. Tanaka (1990)
10.1016/J.JCONREL.2006.07.016
Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhIL11).
A. Takagi (2006)
10.1182/blood.v82.3.1016.bloodjournal8231016
Comparative effects of in vivo treatment using interleukin-11 and stem cell factor on reconstitution in mice after bone marrow transplantation.
X. Du (1993)



This paper is referenced by
Modification of recombinant human interleukin-11 to enhance pharmacologic properties and therapeutic potential
Kuo-ming Yu (2017)
10.1201/9781420076592.CH7
Engineering Of Therapeutic Proteins
Huimin Zhao (2009)
10.1152/ajprenal.00220.2012
Interleukin-11 protects against renal ischemia and reperfusion injury.
H. T. Lee (2012)
Conjugués d'une fraction il-11 et d'un polymère
Deborah H. Charych (2012)
10.3168/jds.2020-19081
Effects of pressure, shear, temperature, and their interactions on selected milk quality attributes.
Jerish Joyner Janahar (2020)
10.1016/j.jconrel.2009.10.015
PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity.
J. Park (2010)
10.1016/j.ejpb.2017.05.013
The pharmacokinetic and pharmacodynamic properties of site‐specific pegylated genetically modified recombinant human interleukin‐11 in normal and thrombocytopenic monkeys
S. Ma (2017)
10.1248/BPB.B16-00434
Sustained Release of Mitomycin C from Its Conjugate with Single-Walled Carbon Nanotubes Associated by Pegylated Peptide.
T. Ohta (2016)
10.1021/mp2004065
Molecular mechanism of improved structural integrity of protein in polymer based microsphere delivery system.
Sanjay Rawat (2012)
10.1111/j.1365-2516.2009.02155.x
Longer‐acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue
G. di Minno (2010)
10.1016/j.lfs.2020.118244
Immunogenicity and toxicokinetics assessment of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.
X. Li (2020)
10.2116/ANALSCI.28.215
Validation of a stability-indicating RP-LC method for the assessment of recombinant human interleukin-11 and its correlation with bioassay.
R. B. Souto (2012)
10.1002/jps.24243
Formulation and stability of cytokine therapeutics.
T. Lipiäinen (2015)
10.1007/978-1-4939-2202-4_7
Strategies to Increase Heterologous Protein Expression in Rice Grains
S. Nandi (2015)
UNIVERSIDADE FEDERAL DE SANTA MARIA CENTRO DE CIÊNCIAS DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS DESENVOLVIMENTO E VALIDAÇÃO DE MÉTODO POR CROMATOGRAFIA LÍQUIDA EM FASE REVERSA PARA AVALIAÇÃO DE INTERLEUCINA-11 HUMANA RECOMBINANTE. CORRELAÇÃO COM O BIOENSAIO
Ricardo Bizogne Souto (2011)
10.1074/jbc.M110.152561
Non-core Region Modulates Interleukin-11 Signaling Activity
Saeko 中冴子 Yanaka 谷 (2010)
10.1016/j.taap.2018.01.016
Preclinical evaluation of the mono‐PEGylated recombinant human interleukin‐11 in cynomolgus monkeys
Kuo-ming Yu (2018)
Novel Strategies in Cocaine Esterase Modification for Treatment of Cocaine Intoxication.
Tien-Yi Lee (2011)
10.1002/PAT.3179
Modification of polyethersulfone membranes using terpolymers engineered and integrated antifouling and anticoagulant properties
Chao He (2013)
10.1095/biolreprod.108.073601
IL11 Antagonist Inhibits Uterine Stromal Differentiation, Causing Pregnancy Failure in Mice1
E. Menkhorst (2009)
10.1073/pnas.1515076112
Interleukin-11 alters placentation and causes preeclampsia features in mice
A. Winship (2015)
10.1016/j.xphs.2018.06.024
Pharmacokinetic and Pharmacodynamic Evaluation of Different PEGylated Human Interleukin-11 Preparations in Animal Models.
Kuo-ming Yu (2018)
Semantic Scholar Logo Some data provided by SemanticScholar